CytRx Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
300.00
100.00
100.00
200.00
100.00
250
SG&A Expense
27,774.00
49,522.90
63,060.50
51,921.00
32,342.10
8,468.70
EBIT
27,594.40
49,605.90
63,278.10
-
32,871.50
8,248.10
Unusual Expense
20,210.10
19,051.20
4,437.60
3,827.60
1,367.80
527
Non Operating Income/Expense
183.00
132.10
20.20
159.20
16.30
2.70
Interest Expense
-
-
-
2,754.70
3,831.20
1,715.70
Pretax Income
47,483.80
30,117.20
58,586.40
50,770.40
34,985.60
9,078.60
Income Tax
1.60
0.80
0.80
0.80
0.80
0.80
Consolidated Net Income
47,485.40
30,118.00
58,587.20
50,771.20
34,986.40
9,079.40
Net Income
47,485.40
30,118.00
58,587.20
50,771.20
34,986.40
9,079.40
Net Income After Extraordinaries
47,485.40
30,118.00
58,587.20
50,771.20
34,986.40
5,445.20
Net Income Available to Common
47,485.40
30,118.00
58,587.20
50,771.20
34,986.40
12,713.60
EPS (Basic)
8.66
3.30
5.82
22.55
1.46
0.41
Basic Shares Outstanding
5,481.90
9,061.90
10,080.50
2,251.80
24,042.30
30,947.70
EPS (Diluted)
8.66
3.32
5.81
22.55
1.46
0.41
Diluted Shares Outstanding
5,481.90
9,061.90
10,080.50
2,251.80
24,042.30
30,947.70
EBITDA
27,474.00
49,422.90
62,960.50
51,721.00
32,242.20
8,218.70
Non-Operating Interest Income
137.70
305.30
234.00
255.10
365.60
355.60

About CytRx

View Profile
Address
11726 San Vicente Boulevard
Los Angeles California 90049
United States
Employees -
Website http://www.cytrx.com
Updated 07/08/2019
CytRx Corp. operates as a biopharmaceutical research and development company specializing in oncology. It focuses on discovering, developing, and commercializing new therapeutics to treat patients with cancer; including aldoxorubicin, a modified version of the widely-used chemotherapeutic agent, doxorubicin. The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.